Pathios Therapeutics Email Format
Biotechnology ResearchEngland, United Kingdom11-50 Employees
Pathios Therapeutics is a biotechnology research company focused on GPCR drug development, with a principal emphasis on GPR65 as an immunology target linked to multiple human diseases. Its clinical-stage oncology program investigates GPR65 using genetic insights, transcriptomics, and functional immunology to understand how this receptor acts as an immune cell sensor of acidosis across different pathological environments. The aim is to develop therapies addressing a broad spectrum of malignancies. The company is based in Oxford, Oxfordshire, and pursues collaborations with strategic external partners to advance its science. In addition to oncology, Pathios is building an emerging pipeline in neuroinflammatory and neurodegenerative disorders by exploring the broader immune roles of GPR65 in microglia and related cell types. It participates in the M:M Bio ecosystem, combining experienced drug discovery leadership with agile, scalable infrastructure intended to support efficient, focused work and a positive place to work.